home / stock / jnj / jnj articles

JNJ Articles, Johnson & Johnson - From 06/17/24

Stock Information
Company Name: Johnson & Johnson
Stock Symbol: JNJ
Market: NYSE
Website: johnson.ca
Menu
JNJ JNJ Quote JNJ Short JNJ News JNJ Articles JNJ Message Board
Get JNJ Alerts

News, Short Squeeze, Breakout and More Instantly...
Market Analysis: Johnson & Johnson And Competitors In Pharmaceuticals Industry | Benzinga

In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive compa...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields | Benzinga

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks...

Johnson & Johnson To Pay $700M To Settle Multi-State Talc Investigation | Benzinga

In a significant development, Johnson & Johnson (NYSE:JNJ) has agreed to pay a hefty sum to resolve a multi-state investigation into its talc-b...

AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability | Benzinga

AbbVie Inc’s (NYSE:ABBV) top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-pric...
Halozyme's ENHANZE Product Gets New Patent Grant in EU | Benzinga

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...

Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial | Benzinga

A jury has ruled that Johnson & Johnson (NYSE:JNJ) must pay $260 million to an Oregon woman who claims to have developed mesothelioma from usin...

Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients | Benzinga

Monday, Johnson & Johnson (NYSE:JNJ) announced longer-term data from Phase 1/2 MajesTEC-1 study of Tecvayli (teclistamab-cqyv) showing deep and...
Performance Comparison: Johnson & Johnson And Competitors In Pharmaceuticals Industry | Benzinga

In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this ar...

Why Sarepta Therapeutics Stock Is Rising Today | Benzinga

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap...

Should You Invest in the iShares U.S. Healthcare ETF? | Benzinga

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (ARCA:IYH), ...
Previous 10 Next 10